Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Diagnosed Anemia Linked to Crohn’s Disease Risk

By LabMedica International staff writers
Posted on 28 Sep 2020
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). More...
IBD is a chronic inflammatory gastrointestinal disorder that involves complex interactions among genetic, environmental, immunological, and microbiological factors.

Anemia can be caused by a variety of etiologies such as iron deficiency, chronic diseases, vitamin B12 or folate deficiency, and genetic factors. Anemia is a known risk factor for cardiovascular diseases, dementia, and chronic medical illness, leading to an increase in all-cause mortality.

Medical scientists from the Seoul National University College of Medicine (Seoul, South Korea) conducted a population-based study from a database for patients during 2009, during which time 9,962,064 individuals older than 20 years, who participated in the national health screening program. Anemia was defined as a hemoglobin level less than 13 g/dL in men and less than 12 g/dL in women. The investigators compared the rate of newly diagnosed IBD in anemic and non-anemic patients.

The team reported that during the mean follow-up period of 7.3 years, the incidences of CD and UC in anemic patients were 2.89 and 6.88 per 100,000 person-years, respectively. The risk of CD was significantly higher in anemic patients than in non-anemic individuals [adjusted hazard ratio (aHR), 2.084; 95% confidence interval (CI), 1.769–2.455]. The risk of CD development was inversely proportional to the hemoglobin concentration. A J-curve relationship was observed between age and the risk of CD in anemic patients. The risk of CD in male anemic patients was significantly higher than that in female anemic patients (aHR, 1.432 versus 1.240, respectively). By contrast, there was no statistically significant difference in the risk of developing UC in anemic and non-anemic individuals (aHR, 0.972; 95% CI, 0.880–1.073).

The risk of CD development was correlated with the severity of anemia as determined by the hemoglobin level. When patients were stratified with respect to hemoglobin levels, the risk of CD was 3.3 times higher in the lowest 10% group than in the highest 10% group. Jong Pil Im, MD, PhD, a professor of Internal Medicine and a senior author of the study, said, “To the best of our knowledge, this is the first epidemiological study to demonstrate the association between anemia and the development of inflammatory bowel disease in the general population.”

The authors concluded that patients with anemia, especially newly developed anemia, were associated with an increased risk of developing CD, not UC. The risk of developing CD was inversely proportional to the hemoglobin level, which was a marker for anemia severity. A J-curve relationship was observed between age and the risk of developing CD among anemic patients, similar to that observed for the incidence of CD based on age. The study was published on September 8, 2020 in the journal PLOS ONE.

Related Links:
Seoul National University College of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
Electrolyte Analyzer
BKE-B
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.